HIV Drug Buyers Want Gilead Product Switch Claims Revived

By Bryan Koenig

Insurers and benefit plans are asking the Ninth Circuit to revive a chunk of their antitrust case against Gilead, arguing their claims that Gilead delayed generic competition to its HIV drugs by monopolizing the market should have new life.

 Brief attached | Read full article » | Save to favorites »